Business Description
Innopharmax Inc
NAICS : 325412
SIC : 2834
ISIN : TW0004172002
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.08 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.34 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 17.8 | |||||
Beneish M-Score | 7.19 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -34.3 | |||||
3-Year EBITDA Growth Rate | -22.5 | |||||
3-Year EPS without NRI Growth Rate | -12.7 | |||||
3-Year FCF Growth Rate | 5.7 | |||||
3-Year Book Growth Rate | -6.3 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62.81 | |||||
9-Day RSI | 62.84 | |||||
14-Day RSI | 59.84 | |||||
6-1 Month Momentum % | -36.24 | |||||
12-1 Month Momentum % | -17.98 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.57 | |||||
Quick Ratio | 4.91 | |||||
Cash Ratio | 4.49 | |||||
Days Inventory | 247.15 | |||||
Days Sales Outstanding | 47.81 | |||||
Days Payable | 34.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7 | |||||
Shareholder Yield % | -7.07 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 37.89 | |||||
Operating Margin % | -140.73 | |||||
Net Margin % | -153.74 | |||||
FCF Margin % | -105.42 | |||||
ROE % | -14.95 | |||||
ROA % | -13.63 | |||||
ROIC % | -17.94 | |||||
ROC (Joel Greenblatt) % | -231.19 | |||||
ROCE % | -14.36 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 32.02 | |||||
PB Ratio | 3.26 | |||||
Price-to-Tangible-Book | 3.3 | |||||
EV-to-EBIT | -20.12 | |||||
EV-to-EBITDA | -22.42 | |||||
EV-to-Revenue | 30.76 | |||||
EV-to-FCF | -29.28 | |||||
Price-to-Median-PS-Value | 1.46 | |||||
Price-to-Net-Current-Asset-Value | 11.01 | |||||
Price-to-Net-Cash | 14.95 | |||||
Earnings Yield (Greenblatt) % | -4.97 | |||||
FCF Yield % | -3.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Innopharmax Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 46.073 | ||
EPS (TTM) (NT$) | -0.77 | ||
Beta | 0.34 | ||
Volatility % | 77.97 | ||
14-Day RSI | 59.84 | ||
14-Day ATR (NT$) | 0.577338 | ||
20-Day SMA (NT$) | 15.62 | ||
12-1 Month Momentum % | -17.98 | ||
52-Week Range (NT$) | 14.4 - 34 | ||
Shares Outstanding (Mil) | 94.99 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Innopharmax Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Innopharmax Inc Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
Innopharmax Inc Frequently Asked Questions
What is Innopharmax Inc(ROCO:4172)'s stock price today?
When is next earnings date of Innopharmax Inc(ROCO:4172)?
Does Innopharmax Inc(ROCO:4172) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |